Clinical Ophthalmology (Feb 2022)
Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease
Abstract
Nandini Venkateswaran,1 Yandong Bian,1 Preeya K Gupta2 1Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, MA, USA; 2Triangle Eye Consultants, Cary, NC, USACorrespondence: Preeya K Gupta, Email [email protected]: Dry eye disease (DED) is a prevalent ocular surface disease. Like with any chronic disease, patients with DED can experience episodic flares. There are many existing and upcoming treatments for the chronic treatment of DED, yet treatments for DED flares are limited. Loteprednol etabonate 0.25% is an FDA approved treatment modality for the short-term treatment of the signs and symptoms of DED. This medication is formulated with the customized mucus-penetrating particle (MPP) technology, which has a greater ability to penetrate the ocular surface and more effectively deliver the active steroid to the ocular surface tissues as compared with conventional steroid preparations. There is also increasing utility of loteprednol etabonate 0.25% in the treatment of DED before and/or after cataract or refractive surgery or as induction therapy prior to starting chronic immunomodulatory medication for DED.Keywords: dry eye disease, dry eye disease flares, loteprednol etabonate 0.25%, mucus penetrating particle technology, ocular surface inflammation
